Vaccine Info

PRV-101 Type 1 Diabetes Vaccine

PRV-101 is a polyvalent coxsackievirus B (CVB) vaccine licensed from Vactech, Ltd., which Provention is developing as a potential vaccine for acute coxsackie infection and for the potential prevention of up to 50% of worldwide type 1 diabetes (T1D) cases.

PRV-101 is currently in an IND-enabling stage prior to initiation of first-in-human studies. Provention plans to initiate a clinical program for PRV-101 beginning with Phase 1 safety, tolerability and proof-of-mechanism studies in adults and children, followed by a proof-of-concept study.

Updated
September 30th, 2019